Poor
Needs Revision
Patient Risk:
Low
Summary
The response accurately identifies anastrozole as a tablet and reflects the labeled 1 mg strength, but most claims concern pricing, generic-versus-brand cost, insurance, or discount cards, none of which are addressed by the supplied FDA label.
Category Scores
Accurate Statements
Anastrozole is available as tablets.
Section 3 states that anastrozole is supplied as white, film-coated tablets.
Unsupported Statements
Anastrozole is commonly available in a 1 mg strength.
The label identifies tablets containing 1 mg of anastrozole but does not establish that this strength is commonly available.
The out-of-pocket price of anastrozole varies by drug strength.
The supplied label contains no pricing or out-of-pocket cost information.
The out-of-pocket price of anastrozole varies by pharmacy.
The supplied label contains no information about pharmacy-specific pricing.
The out-of-pocket price of anastrozole varies depending on whether the cash price or a discount card is used.
The supplied label contains no information about cash prices, discount cards, or payment arrangements.
Generic anastrozole is often much cheaper than branded anastrozole.
The supplied label contains no comparison of generic and branded product prices.
Without insurance, the price difference between generic and branded anastrozole can be large.
The supplied label contains no information about insurance coverage or generic-versus-brand price differences.
The price of anastrozole can vary depending on whether the pharmacy dispenses a generic product or a brand product.
The supplied label contains no information about pharmacy pricing or generic-versus-brand dispensing costs.
Contradictions
Important Omissions
The response does not qualify that its pricing claims are not addressed by the supplied FDA label.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The response makes no dosing, administration, contraindication, warning, interaction, or other treatment-safety claims. Its unsupported content concerns pricing rather than direct patient management.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Needs Revision
Primary Issue
Most pricing-related claims are not supported or addressed by the supplied FDA label.
Suggested Improvement
Retain the tablet and labeled 1 mg statements, revise the word 'commonly' unless independently supported, and remove or explicitly qualify all pricing, insurance, discount-card, and generic-versus-brand cost claims as outside the supplied label.